Global Antiviral Drugs Market Size, Share and Trends Analysis Report, By Type (Branded Drugs and Generic Drugs), By Application (Influenza (Flu) Antiviral Drugs, Hepatitis Antiviral Drugs, HIV Antiviral Drugs, Herpes Antiviral Drugs, and Others), Forecast 2022-2028

The global antiviral drugs market is anticipated to grow at a significant CAGR of 4.0% during the forecast period 2022-2028.  The global antiviral drug market is being driven by an increase in viral diseases such as the Human Immunodeficiency Virus (HIV), influenza A and B, hepatitis B and C, herpes, chickenpox, and papilloma, among others. One of the most common viral infectious illnesses is HIV. According to World Health Organization (WHO), HIV is a serious global public health concern, having claimed the lives of 36.3 million people to date. At the end of 2020, there were an estimated 37.7 million persons living with HIV, with almost two-thirds (25.4 million) residing in the African Region. In 2020, 680 thousand people died from HIV-related causes, while 1.5 million contracted the virus. Hepatitis B is another chronic viral disease highly prevalent globally. In 2019, the WHO had estimated that 296 million individuals had chronic hepatitis B infection, with 1.5 million new cases registered every year. Hepatitis B had caused around 820 thousand deaths in 2019, most of which were due to cirrhosis and hepatocellular carcinoma (primary liver cancer). Furthermore, the market is being driven by a considerable amount of investment in this industry. According to a WHO report, 67 low- and middle-income countries spend $6 billion every year to eradicate hepatitis.

The market is segmented based on type and application. Based on the type, the market is sub-segmented into branded drugs and generic drugs. Based on application, the market is sub-segmented into influenza (Flu) antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, herpes antiviral drugs, and others. Among these applications, the HIV antiviral drugs segment is anticipated to hold a prominent share in the market due to its high prevalence globally. The rise in the adoption of antiviral drugs for the treatment of these infectious diseases is the major cause of the growth of the segment. Additionally, the growing research and development activities for new product launches is propelling the growth of the global antiviral drugs market. For instance, in March 2022, Themis Medicare Ltd. announced the approval of its antiviral drug VIRALEX by the Drug Controller General of India (DCGI). As per the results of double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild to moderate COVID-19 patients.

Some major players in the market include Pfizer Inc., Mylan NV, Dr Reddy’s Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories. among others. The market players are helping significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay in the competition of the market. For instance, in March 2022, Ascletis Pharma Inc. announced that it has further expanded its ritonavir oral tablet production capacity to around 530 million tablets per year, to meet the potential escalation in domestic and global demands. Ascletis has taken multiple measures for expansion of the annual ritonavir production capacity, including adding additional key equipment at the manufacturing facilities of Ascletis Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Ascletis. Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug PAXLOVID (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc., Mylan NV, Dr Reddy’s Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antiviral Drugs Market Report by Segment

By Type

• Branded Drugs
• Generic Drugs

By Application

• Influenza (Flu) Antiviral Drugs
• Hepatitis Antiviral Drugs
• HIV Antiviral Drugs
• Herpes Antiviral Drugs
• Others

Global Antiviral Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa